- Research article
- Open Access
- Open Peer Review
Impact of atypical long-acting injectable versus oral antipsychotics on rehospitalization rates and emergency room visits among relapsed schizophrenia patients: a retrospective database analysis
BMC Psychiatry volume 13, Article number: 221 (2013)
Among schizophrenia patients relapsed on an oral antipsychotic (AP), this study compared the impact of switching to atypical AP long-acting injectable therapy (LAT) versus continuing oral APs on hospitalization and emergency room (ER) visit recurrence.
Electronic records from the Premier Hospital Database (2006-2010) were analyzed. Adult patients receiving oral APs during a schizophrenia-related hospitalization were identified and, upon relapse (i.e., rehospitalization for schizophrenia), were stratified into (a) patients switching to atypical LAT and (b) patients continuing with oral APs. Atypical LAT relapse patients were matched 1:3 with oral AP relapse patients, using a propensity score model. Andersen-Gill Cox proportional hazards models assessed the impact of atypical LAT versus oral AP on time to multiple recurrences of all-cause hospitalizations and ER visits. No adjustment was made for multiplicity.
Atypical LAT (N = 1032) and oral AP (N = 2796) patients were matched and well-balanced with respect to demographic (mean age: 42.1 vs 42.4 years, p = .5622; gender: 43.6% vs 44.6% female, p = .5345), clinical, and hospital characteristics. Over a mean 30-month follow-up period, atypical LATs were associated with significantly lower mean number of rehospitalizations (1.25 vs 1.61, p < .0001) and ER visits (2.33 vs 2.67, p = .0158) compared with oral APs, as well as fewer days in hospital (mean days: 13.46 vs. 15.69, p = .0081). Rehospitalization (HR 0.81, 95% CI 0.76–0.87, p < .0001) and ER visit (HR 0.88, 95% CI 0.87–0.93, p < .0001) rates were significantly lower for patients receiving atypical LAT versus oral APs.
This hospital database analysis found that in relapsed schizophrenia patients, atypical LATs were associated with lower rehospitalization and ER visit rates than oral APs.
Schizophrenia usually appears in early adulthood, and approximately two-thirds of individuals with this disease have persisting or fluctuating symptoms even with optimal treatment [1, 2]. Inpatient care represents the primary driver of costs associated with schizophrenia, accounting for between one-third and two-thirds of the total direct health care costs of patients with schizophrenia [3–6]. Indeed, most of these patients will experience a chronic course with many relapses, characterized by an exacerbation of psychosis, emergency room (ER) visits, and rehospitalizations [7–9]. These relapse events are often associated with significant changes in the treatment of schizophrenia and initiation of new therapies [10, 11].
The primary goal of pharmacotherapy with antipsychotics (APs) in patients with schizophrenia is to prevent relapse and to reduce the severity of subsequent acute episodes over time [12, 13]. Compared with typical APs, atypical APs are generally considered to be associated with a lower risk of serious adverse events and are therefore the first-line therapeutic agents of choice for patients with schizophrenia in most countries [14–16]. In practice, the effectiveness of oral AP treatment is often undermined by poor adherence , which is associated with an increased frequency of relapse and hospitalization rates, more severe symptoms, longer inpatient stays, and higher hospital costs [18–21].
It has been shown that AP long-acting injectable therapy (LAT) can significantly improve adherence, reduce symptoms, and reduce the risk of relapse and rehospitalization, particularly for severely ill patients [9, 22, 23]. There are currently three atypical APs available in long-acting forms: risperidone (RISPERDAL® CONSTA®), paliperidone palmitate (INVEGA® SUSTENNA®), and olanzapine (ZYPREXA® RELPREVV®) [24–26]. Risperidone is indicated for the treatment of schizophrenia as one injection every 2 weeks, whereas paliperidone palmitate is a once-a-month agent approved for the acute and maintenance treatment of schizophrenia in adults [24, 25]. Olanzapine is approved for the treatment of schizophrenia as one injection every 2 to 4 weeks but is available only through a restricted distribution program . Because there is to date limited use of olanzapine LAT in clinical practice and given its markedly different profile from the two other atypical AP LATs, this analysis focused on risperidone and paliperidone palmitate LATs.
Most previous studies have found a beneficial effect of atypical LATs in terms of rehospitalizations using a pre-post study design, where each patient acted as his or her own control [9, 20, 22, 27–37]. In addition, previous studies mostly focused on the rate of rehospitalization, not taking into account that hospitalizations and ER visits may be recurrent events in this population. This study used a matched-cohort design to compare the effect of switching from oral APs to atypical LATs (risperidone or paliperidone palmitate) with that of continuing to take oral APs on the recurrence of hospitalizations and ER visits among patients with schizophrenia who relapsed.
Health Insurance Portability and Accountability Act fully compliant, deidentified records were retrieved retrospectively from the Premier Perspective Comparative Hospital Database (Premier), the largest hospital-based database in the United States, covering from the first quarter of 2006 to the fourth quarter of 2010. This database provides detailed information for more than 45 million inpatient discharges and 310 million hospital outpatient visits from more than 600 acute care hospitals across all US regions. Data elements included demographics (e.g., age, gender, marital status, race, payer type), visit-level information (e.g., primary and secondary diagnoses), hospital characteristics (e.g., urban, teaching, number of beds, region), and detailed drug use information (e.g., drug name, dosage strength, dispensed quantity). As opposed to centralized health care claims recorded by insurance companies, patients’ medical information available in the Premier database comes from records collected for billing purposes at the hospital level. Institutional review board (IRB) and informed consent were not required for this study.
A retrospective cohort design was used to identify patients with schizophrenia treated with APs who relapsed. More specifically, the study included adult patients (aged at least 18 years) receiving oral APs during a first schizophrenia-related hospitalization (defined as hospitalizations with (i) a primary or admitting diagnosis of schizophrenia according to International Classification of Diseases, 9th Revision, Clinical Modification [ICD-9-CM]: 295.xx; (ii) a primary or admitting diagnosis of other mental disorders [ICD-9-CM diagnosis: 290.xx-294.xx, 296.xx-319.xx] and an accompanying diagnosis of schizophrenia, or (iii) a primary or admitting diagnosis of injury and poisoning [ICD-9-CM diagnosis: 800.xx-999.xx] and an accompanying diagnosis of schizophrenia). Patients were further stratified upon the next schizophrenia rehospitalization (i.e., schizophrenia relapse) into the following mutually exclusive exposure groups: (a) patients switching to paliperidone palmitate or risperidone injectable (“atypical LAT group”) and (b) patients continuing with oral APs (“oral AP group”). The index hospitalization (i.e., schizophrenia relapse) had to occur at least 3 months before the data cutoff date (December 2010). Figure 1 depicts the study design scheme for this population.
Study end points
End points for this study were the number of rehospitalizations and the number of ER visits occurring after the index hospitalization, which are avoidable events representing relapses not managed through outpatient services. Number of days in hospital over the entire observation period was reported. ER visits resulting in hospitalizations counted as one event for the latter end point. Additionally, the time to first rehospitalization (or ER visit) was defined as the number of months between the index hospitalization and the first rehospitalization (or ER visit) during follow-up. Finally, the frequency of events within the same month or within 1, 3, and 6 months after the index hospitalization was also reported. As depicted in Figure 1, these study end points were evaluated from the index hospitalization (i.e., relapse) to the data cutoff date (December 31, 2010). In addition, results were generated separately for all-cause visits, mental disorder–related visits (at least one diagnosis for mental disorders [ICD-9-CM diagnosis: 290.xx-319.xx]), and schizophrenia-related visits (at least one diagnosis for schizophrenia [ICD-9-CM diagnosis: 295.xx]).
To minimize the potential of confounding factors, each patient in the atypical LAT group was matched with up to three unique patients in the oral AP group based on both propensity scores, using the 2.5 percentiles of the propensity score distribution and exact matching factors. These criteria were chosen to achieve both clinical and statistical balance between cohorts without losing a significant proportion of the atypical LAT group. Propensity scores were calculated using a multivariate logistic regression model in which being in the atypical LAT group was the dependent variable and characteristics available at the first hospitalization (type of oral AP used) and at the index hospitalization (sociodemographic characteristics, hospital characteristics, and clinical characteristics [e.g., admitting and primary diagnoses, admitting and attending physician specialty, length of ER stay, degree of severity, number of distinct AP agents used, type of oral AP agents received during the first hospitalization, suicidal behavior, surgery, discharge status, year of admission, time between first hospitalization and index hospitalization, and time between index hospitalization and data cutoff date]) were used as predictors of being in the atypical LAT group. Exact matching factors included schizophrenia as the primary diagnosis, categories of index hospitalization length of stay, psychiatry admitting physician specialty, and the number of AP agents used during the index hospitalization.
Descriptive statistics were generated to summarize baseline characteristics and study end points. Frequency counts and percentages were used to summarize categorical variables while means and standard deviations were used for continuous variables. To adjust for the non-independence of the matched cohorts, statistical differences between cohorts were assessed using McNemar tests for categorical variables and the paired two-sided t tests for continuous variables.
Since a patient might experience multiple recurrences of hospitalizations and of ER visits, the Andersen-Gill extension of the Cox proportional hazard model was used to assess the impact of atypical LAT versus oral AP on the time to recurrences of these events . In this extension, a subject contributes to the risk set for an event as long as the patient is under observation at the time the event occurs. Along with the hazard ratio, 95% confidence limits and p values were estimated. The analysis was conducted for all-cause visits and for the subset of mental disorder-related visits (at least one diagnosis of mental disorders [ICD-9-CM code: 290-319]) and of schizophrenia-related visits (at least one diagnosis for schizophrenia [ICD-9-CM diagnosis: 295.xx]). A two-sided alpha error of 0.05 was used to declare statistical significance. No adjustment was made for multiplicity. All statistical analyses were conducted using SAS® Version 9.2 (SAS Institute, Inc., Cary, NC, USA).
Among the 122,129 patients receiving oral APs in their first AP hospitalization, 1092 patients switched to an atypical LAT during a second schizophrenia-related hospitalization (whereas 35,841 patients continued to take oral APs). Among these patients, a total of 1032 atypical LAT patients (94.5% of all patients) were matched with 2796 oral AP patients. The baseline demographics and clinical characteristics of the matched populations at the index hospitalization are shown in Table 1. Atypical LAT and oral AP groups appeared well balanced with respect to mean age (42.1 vs 42.4 years, p = .5622), gender (43.6% vs 44.6% female, p = .5345), race, region, payer type, hospital characteristics, admitting diagnosis, admitting physician specialty, and degree of illness severity (p > .05 for all). The mean length of stay (16.3 vs 16.0 days, p = .6142), the mean time between first hospitalization and the index hospitalization (8.0 vs 7.5 months, p = .1186), and the mean time between index hospitalization and data cutoff date (29.8 vs 30.3 months, p = .2953) appeared to be not statistically significantly different between atypical LAT and oral AP groups.
Rehospitalizations and emergency room visits
Table 2 presents descriptive statistics on rehospitalization rates and ER visits after the index hospitalization. Over a mean 30-month follow-up period, atypical LAT patients were associated with a significantly lower mean number of all-cause rehospitalizations (1.25 vs 1.61, p < .0001), mental disorder-related rehospitalizations (1.24 vs 1.59, p < .0001), schizophrenia-related rehospitalizations (1.15 vs 1.41, p = .0005), and all-cause ER visits (2.33 vs 2.67, p = .0158) compared with oral AP patients. The frequency of all-cause rehospitalizations within the same month (0.07 vs 0.09, p = .0688), within 1 month (0.15 vs 0.20, p = .0286), within 3 months (0.30 vs 0.38, p = .0288), and within 6 months (0.48 vs 0.58, p = .0029) was consistently lower for the atypical LAT group than for the oral AP group. Similarly, frequencies for mental disorder-related rehospitalizations were significantly lower for the atypical LAT group than for the oral AP (same month: 0.07 vs 0.09, p = .0786; 1 month: 0.15 vs 0.20, p = .0360; 3 months: 0.30 vs 0.37, p = .0333; and 6 months: 0.48 vs 0.58, p = .0032). All-cause and mental disorder-related mean days in hospital were also smaller for the atypical LAT cohort (all-cause: 13.46 vs. 15.69, p = .0081; mental disorder-related: 13.44 vs. 15.62, p = .0093, schizophrenia-related: 12.79 vs. 14.28, p = .0893).
Recurrence of events
Figure 2 presents the results of the Cox proportional hazards model with recurrent events using the Andersen-Gill extension. The risk of all-cause rehospitalizations was significantly lower for the atypical LAT group than for the oral AP group (hazard ratio [HR] 0.81, 95% confidence interval [CI] 0.76–0.87, p < .0001). Consistently significant results were found for all-cause ER visits (HR 0.88, 95% CI 0.87–0.93, p < .0001).
Similarly, significantly lower risks for mental disorder-related events were observed for atypical LAT patients relative to oral AP patients (rehospitalizations: HR 0.85, 95% CI 0.80–0.91, p < .0001; ER visits: HR 0.94, 95% CI 0.88–0.99, p = .0285). A lower risk of schizophrenia-related rehospitalizations was found for the atypical LAT group (HR: 0.88, 95% CI 0.82-0.95, p = .0007), whereas no difference between cohorts was found for schizophrenia-related emergency-room visits (HR: 0.99, 95% CI 0.92-1.05, p = .6851).
This real-world retrospective study compared the recurrence of hospitalizations and ER visits between relapsed patients with schizophrenia treated with atypical LATs and those treated with oral AP agents. The results showed a 19% to 12% significantly lower likelihood of all-cause rehospitalizations and ER visits for the atypical LAT group relative to the oral AP group. Results were similar when restricting the analysis to the subset of events associated with a diagnosis for mental disorders.
In the absence of direct clinical assessment data, this study used rehospitalizations and ER visits as a proxy for instances of relapses. This is warranted as hospitalizations are related to a wide range of schizophrenic outcomes such as suicidal attempt, violence, and medication side effects [9, 27, 39–41]. Schizophrenia disease is often characterized by episodes of relapse alternating with periods of complete or partial remission . Successive relapses can reduce the degree and duration of the following remission, worsen disability, and increase refractoriness to future treatment [8, 42]. Relapses are associated with high medical and non-medical costs as well as productivity loss . Thus, rehospitalization, which is frequently the most expensive healthcare cost component for psychotic patients, is a relevant relapse measure .
Rehospitalizations and ER visits were analyzed in a relapsed population. Patients receiving atypical LAT instead of oral AP may be more difficult to treat, with poorer adherence to medication and/or with more severe symptoms. In the absence of patients’ complete medical history, imposing a previous hospitalization with AP utilization prior to the index hospitalization served as an exact matching criterion to identify similar groups of patients. Along with the choice of the study design, the matching algorithm used in the current study contributed to diminishing the risk of selection bias resulting from confounding factors between groups. A comprehensive list of demographics and clinical characteristics available during the index hospitalization was included in the exact matching algorithm and propensity scores model. Moreover, the sample sizes allowed the authors to match each atypical LAT patient with up to three oral AP patients, thus increasing the statistical power of the analyses.
The descriptive results of this study showed that atypical LAT patients had a significantly lower rate of rehospitalizations compared with oral AP patients in addition to a non-significantly longer time period between the index hospitalization and the first rehospitalization (Table 2). These two factors were combined in one statistical analysis, the Andersen-Gill extension of the Cox regression model, to calculate the risk of time to multiple recurrences of hospitalizations and ER visits. The Andersen-Gill model uses a counting process approach which relates the intensity function of event recurrences to the covariates multiplicatively where all events contribute equally to the hazard function. The hazard ratios of recurrent events calculated using this method confirmed the descriptive results that patients using atypical LATs have a lower risk of rehospitalizations and ER visits compared with oral AP patients.
This study corroborates the findings from other studies that have found a beneficial effect of atypical LATs in terms of rehospitalizations [9, 20, 22, 27–37]. Some of these studies used a pre-post study design, where each patient acted as his or her own control, and found that LATs were associated with a decrease in hospitalizations ranging from 34% to 89% [20, 22, 27–34]. The current analysis based on a matched cohort design found that LATs were associated with a 19% reduction in the risk of recurrence of hospitalizations when compared to matched oral AP patients. The slightly smaller effect found in the current analysis may be explained in part by the study design, where the comparison was made on relapsed oral AP patients, which are likely an healthier population than the subset of patients switching to LATs (and hence are expected to have fewer rehospitalizations). Focusing on the relapsed population (patients already experiencing a second schizophrenia-related hospitalization) and the matching approach have helped to address this bias, but it is possible that unobservable characteristics were still different between cohorts, therefore explaining the smaller effect found here. However, the general consistency of the results throughout different methods, study designs, and study populations suggests that atypical LATs may be more effective than oral APs in avoiding patient relapse. Moreover, it has been shown that inpatient care can account for up to two-thirds of the total direct healthcare costs for schizophrenia patients in the U.S. [3, 4, 6]. Thus, the 19% decrease in the risk of recurrence of rehospitalization found in the current study suggest that the increased use of LATs compared to oral AP may be associated with substantial cost savings in relapsed patients with schizophrenia. Further studies analyzing costs of hospitalizations between patients using atypical LATs and matched oral AP patients are warranted.
The present study has several limitations: (a) The data were subject to billing inaccuracies and missing data. (b) As the Premier network regroups only a subset of facilities in the United States, the history of rehospitalizations and ER visits for a given patient may be incomplete. Moreover, it was not possible in the Premier database to link patient records across facilities, and, therefore, to know whether or not the entire continuum of care of patients was captured. (c) Patients were matched based only on information available during hospitalizations occurring at the same hospital as no information on services received outside the hospital or on pharmacy utilization was available, potentially limiting the ability to fully adjust for differences in baseline severity of the disease. Additionally, rehospitalizations recorded in the database were only those occurring at the same hospital. Therefore, the rates of hospitalization may be underestimated; however, it can be assumed that the rates were underreported equivalently between cohorts. (d) The lack of clinical data (e.g., PANSS score) prevented us from assessing patients’ disease severity and/or the occurrence of a clinically validated relapse event. Although all these limitations exist, they should not have introduced bias in one cohort versus the other because neither impacts the relative differences found between cohorts.
This large hospital database analysis demonstrated that relapsed patients with schizophrenia treated with atypical LATs were associated with a 19% lower likelihood of rehospitalizations compared with patients receiving oral APs. Atypical LATs were also associated with significantly lower ER visit rates and mental disorder-related and schizophrenia-related rehospitalization rates compared with oral APs. These findings suggest that the efficacy and patient tolerability benefits associated with improved patient adherence to the injectable form of the second-generation antipsychotics reduce the demand for hospitalizations and ER visits among relapsed patients with schizophrenia. In addition to the clinical benefits, atypical LATs offer promise for cost savings because of reduced inpatient hospital utilization.
Saha S, Chant D, Welham J, McGrath J: A systematic review of the prevalence of schizophrenia. PLoS Med. 2005, 2 (5): e141-10.1371/journal.pmed.0020141.
American Psychiatric Association: Diagnostic and statistical manual of mental disorders: DSM-IV. 1994, Washington, DC: American Psychiatric Association, 4
Nicholl D, Akhras KS, Diels J, Schadrack J: Burden of schizophrenia in recently diagnosed patients: healthcare utilization and cost perspective. Curr Med Res Opin. 2010, 26 (4): 943-955. 10.1185/03007991003658956.
Wu EQ, Birnbaum HG, Shi L, Ball DE, Kessler RC, Moulis M, Aggarwal J: The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry. 2005, 66 (9): 1122-1129. 10.4088/JCP.v66n0906.
Ascher-Svanum H, Zhu B, Faries D, Ernsrt FR: A comparison of olanzapine and risperidone on the risk of psychiatric hospitalization in the naturalistic treatment of patients with schizophrenia. Ann Gen Hosp Psychiatry. 2004, 3 (1): 11-10.1186/1475-2832-3-11.
Weiden PJ, Olfson M: Cost of relapse in schizophrenia. Schizophr Bull. 1995, 21: 491-529.
Andreasen NC: Symptoms, signs and diagnosis of schizophrenia. Lancet. 1995, 346: 477-481. 10.1016/S0140-6736(95)91325-4.
De Sena EP, Santos-Jesus R, Miranda-Scippa A, Quarantini L d C, Oliveira IR: Relapse in patients with schizophrenia: a comparison between risperidone and haloperidol. Rev Bras Psiquiatr. 2003, 25 (4): 220-223. 10.1590/S1516-44462003000400007.
Chue P, Llorca PM, Duchesne I, Leal A, Rosillon D, Mehnert A: Hospitalization rates in patients during long-term treatment with long-acting risperidone injection. J Appl Res. 2005, 5 (2): 266-274.
Nyhuis AW, Faries DE, Ascher-Svanum H, Stauffer VL, Kinon BJ: Predictors of switching antipsychotic medications in the treatment of schizophrenia. BMC Psychiatry. 2010, 10: 75-10.1186/1471-244X-10-75.
Faries DE, Ascher-Svanum H, Nyhuis AW, Kinon BJ: Clinical and economic ramifications of switching of antipsychotics in the treatment of schizophrenia. BMC Psychiatry. 2009, 9: 54-10.1186/1471-244X-9-54.
American Psychiatric Association: Practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry. 1997, 154: 1-63.
Kane JM: Pharmacologic treatment of schizophrenia. Biol Psychiatry. 1999, 46: 1396-1408. 10.1016/S0006-3223(99)00059-1.
Tandon R: Safety and tolerability: how do newer generation “atypical” antipsychotics compare?. Psychiatr Q. 2002, 73: 297-311. 10.1023/A:1020464017021.
Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005, 353: 1209-1223. 10.1056/NEJMoa051688.
Valenstein M, Blow F, Copeland L, McCarthy JF, Zeber JE, Gillon L, Bingham CR, Stavenger T: Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors. Schizophr Bull. 2004, 30 (2): 255-264. 10.1093/oxfordjournals.schbul.a007076.
Thieda P, Beard S, Richter A, Kane J: An economic review of compliance with medication therapy in the treatment of schizophrenia. Psychiatr Serv. 2003, 54 (4): 508-513. 10.1176/appi.ps.54.4.508.
Sun SX, Liu GG, Christensen DB, Fu AZ: Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States. Curr Med Res Opin. 2007, 23 (10): 2305-2312. 10.1185/030079907X226050.
Morken G, Widen JH, Grawe RW: Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia. BMC Psychiatry. 2008, 8: 32-10.1186/1471-244X-8-32.
Olivares JM, Rodriguez-Morales A, Diels J, Povey M, Jacobs A, Zhao Z, Lam A: Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: Results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR). Eur Psychiatry. 2009, 24: 287-296. 10.1016/j.eurpsy.2008.12.002.
Masand PS, Roca M, Turner MS, Kane JM: Partial adherence to antipsychotic medication impacts the course of illness in patients with schizophrenia: a review. Prim Care Companion J Clin Psychiatr. 2009, 11 (4): 147-154. 10.4088/PCC.08r00612.
Lambert T, Olivares JM, Peuskens J, DeSouza C, Kozma CM, Otten P, Crivera C, Jacobs A, Macfadden W, Mao L, Rodriguez SC, Dirani R, Akhras KS: Effectiveness of injectable risperidone long-acting therapy for schizophrenia: data from the US, Spain, Australia, and Belgium. Ann Gen Psychiatry. 2011, 10: 10-10.1186/1744-859X-10-10.
Alphs L, Bossie CA, Sliwa JK, Ma YW, Turner N: Onset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trial. Ann Gen Psychiatry. 2011, 10 (1): 12-10.1186/1744-859X-10-12.
RISPERDAL® CONSTA®: (risperidone) Long-Acting Injection product package insert. 2012, Titusville, NJ, USA: Janssen Pharmaceuticals, Inc, December
INVEGA SUSTENNA®: (paliperidone palmitate) product package insert. 2012, Titusville, NJ, USA: Janssen Pharmaceuticals, Inc, September
ZYPREXA RELPREVV®: (olanzapine for extended release injectable suspension) product package insert. 2012, IN, USA: Eli Lilly and Company, Indianapolis, July
Su KP, Chang HC, Tsai SJ, Yen FC, Tang CH: Relapse and long-acting injectable risperidone: a 1-year mirror image study with a national claims database in Taiwan. Value Health. 2009, 12 (suppl 3): S118-S121.
Taylor M, Currie A, Lloyd K, Price M, Peperell K: Impact of risperidone long acting injection on resource utilization in psychiatric secondary care. J Psychopharmacol. 2008, 22 (2): 128-131. 10.1177/0269881107084068.
Fernandez-Miranda J, Caramés-García V, Sánchez-García A: Tolerability and adherence of risperidone long acting injectable (RLAI) in severe schizophrenic patients. 2009, San Francisco, CA: Presented at the American Psychiatric Association 162nd Annual Meeting, May 16-21, (Abstract No. NR6-040)
Apiquian R, Córdoba R, Louzã M: Clinical outcomes of long-acting injectable risperidone in patients with schizophrenia: six-month follow-up from the Electronic Schizophrenia Treatment Adherence Registry in Latin America. Neuropsychiatr Dis Treat. 2010, 7: 19-26.
Ren XS, Crivera C, Sikirica M, Dirani R, Qian S, Kazis LE: Evaluation of health services use following the initiation of risperidone long-acting therapy among schizophrenia patients in the Veterans Health Administration. J Clin Pharm Ther. 2010, 36 (3): 383-389.
Willis M, Svensson M, Löthgren M, Eriksson B, Berntsson A, Persson U: The impact on schizophrenia-related hospital utilization and costs of switching to long-acting risperidone injections in Sweden. Eur J Health Econ. 2010, 11 (6): 585-594. 10.1007/s10198-009-0215-9.
Kozma CM, Slaton T, Dirani R, Fastenau J, Gopal S, Hough D: Changes in schizophrenia-related hospitalization and ER use among patients receiving paliperidone palmitate: results from a clinical trial with a 52-week open-label extension (OLE). Curr Med Res Opin. 2011, 27 (8): 1603-1611. 10.1185/03007995.2011.595000. Epub 2011 Jun 22
Koczerginski D, Arshoff L: Hospital resource use by patients with schizophrenia: reduction after conversion from oral treatment to risperidone long-acting injection. Healthc Q. 2011, 14 (1): 82-87. 10.12927/hcq.2011.22077.
Simpson GM, Mahmoud RA, Lasser RA, Kujawa M, Bossie CA, Turkoz I, Rodriguez S, Gharabawi GM: A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry. 2006, 67 (8): 1194-1203. 10.4088/JCP.v67n0804.
Beauclair L, Chue P, McCormick J, Carmacho F, Lam A, Luong D: Impact of risperidone long-acting injectable on hospitalisation and medication use in Canadian patients with schizophrenia. J Med Econ. 2007, 10: 427-442. 10.3111/13696990701646825.
Fuller M, Shermock K, Russo P, Secic M, Dirani R, Vallow S, Flanders S: Hospitalisation and resource utilisation in patients with schizophrenia following initiation of risperidone long-acting therapy in the Veterans Affairs Healthcare System. J Med Econ. 2009, 12 (4): 317-324. 10.3111/13696990903303902.
Andersen PK, Gill RD: Cox’s regression model for counting processes: a large sample study. Ann Stat. 1982, 10: 1100-1120. 10.1214/aos/1176345976.
Burns T, Fiander M, Audini B: A delphi approach to characterising “relapse” as used in UK clinical practice. Int J Soc Psychiatry. 2000, 46 (3): 220-230. 10.1177/002076400004600308.
Hui CLM: Relapse in schizophrenia. Hong Kong Med Diary. 2011, 16 (5): 8-9.
Hogarty GE, Ulrich RF: The limitations of antipsychotic medication on schizophrenia relapse and adjustment and the contributions of psychosocial treatment. J Psychiatr Res. 1998, 32 (3–4): 243-250.
Wyatt RJ: Neuroleptics and the natural course of schizophrenia. Schizophr Bull. 1991, 17 (2): 325-351. 10.1093/schbul/17.2.325.
The pre-publication history for this paper can be accessed here:http://0-www.biomedcentral.com.brum.beds.ac.uk/1471-244X/13/221/prepub
The authors wish to thank ApotheCom for assistance with preparing the manuscript for journal submission.
M-H Lafeuille, F Laliberté-Auger, and P Lefebvre are employees of Groupe d’analyse, Ltée.
C Frois and MS Duh are employees of Analysis Group, Inc.
J Fastenau is an employee of Janssen Scientific Affairs, LLC, and a Johnson & Johnson stockholder.
MHL, FL-A, PL, CF, MSD, JF were responsible for the design, data collection, and writing. MHL, FL-A, PL, and MSD were responsible for the statistical analyses. All authors read and approved the final manuscript.
About this article
Cite this article
Lafeuille, M., Laliberté-Auger, F., Lefebvre, P. et al. Impact of atypical long-acting injectable versus oral antipsychotics on rehospitalization rates and emergency room visits among relapsed schizophrenia patients: a retrospective database analysis. BMC Psychiatry 13, 221 (2013) doi:10.1186/1471-244X-13-221
- Long-acting atypical antipsychotic
- Oral antipsychotics
- Andersen-Gill extension
- Cox proportional hazards models